Floatz Rating
D28/100
Confidence
Indicative
Sponsor
Peking Union Medical College Hospital
Modality
radiopharmaceutical
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05170555CT.gov Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 68ga-psma (this asset) | Peking Union Medical College Hospital | N/A | D · 28 |
| Sorafenib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BBB |
| Pazopanib | Imbioray (Hangzhou) Biomedicine Co., Ltd. | P4 | BBB |
| Belzutifan | Vall d'Hebron Institute of Oncology | P3 | BB |
| Alpha-Interferon | Fuzhou General Hospital | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P4 | BB |
| Everolimus | Merck Sharp & Dohme LLC | P4 | BB |
| Interferon-Alfa-2A | Central European Society for Anticancer Drug Research | P3 | BB |
| Axitinib | SWOG Cancer Research Network | P4 | BB |
+42 more in the Renal Cell Carcinoma cohort
Other indications for 68ga-psma
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | B · 59 |
| Metastatic Prostate Carcinoma | — | P2 | CCC · 52 |
| Prostate Adenocarcinoma | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 68ga-psma in Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68ga-psma-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →